Combination cancer therapy : modulators and potentiators / edición, Gary K. Schwartz.

Colaborador(es):

Schwartz, Gary K [ed.]

Tipo de material: Texto

TextoIdioma: Inglés Series Cancer drug discovery and developmentDetalles de publicación: Totowa, N.J. : Humana, 2005Descripción: 284 p. : il., gráf. ; 23 cmISBN:

1588292002
9781588292001

Otro título:

Modulators and potentiators

Tema(s):

Clasificación LoC:

RC271.C5 O4 2005

Recursos en línea:

Contenidos parciales:

1. Targeting of the EGFR as a modulator of cancer chemotherapy.-- 2. Cyclin-dependent kinase inhibitors in combination chemotherapy.-- 3. Development of protein kinase C and cyclin-dependent kinase inhibitors as potentiators of cytotoxic drug action in leukemia.-- 4. Carboxyamidotriazole, an inhibitor of nonvoltage-operated calcium entry: single-agent and combination therapy for ovarian carcinoma.-- 5. Targeted F-particle therapy: a rational approach to drug development in hematologic diseases and solid tumors.-- 6. Pharmacological modulation of fluoropyrimidines: building on the lessons of the past.-- 7. Development of inhibitors of HER2 with taxanes: new directions in breast cancer therapy.-- 8 Targeting NF-PB to increase the activity of cisplatin in solid tumors.-- 9. Combinations of chemotherapy and G3139, an antisense Bcl-2 oligonucleotide.-- 10. Use of animal models to evaluate signal transduction inhibitors as modulators of cytotoxic therapy.

Alcance y contenido: Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

Etiquetas de esta biblioteca: No hay etiquetas de esta biblioteca para este título. Ingresar para agregar etiquetas.

Existencias ( 1 )
Notas de título ( 4 )

Existencias
Tipo de ítem	Biblioteca actual	Colección	Signatura topográfica	Copia número	Estado	Fecha de vencimiento	Código de barras
01-Préstamo Interno (Libros)	Biblioteca Magna a	Acervo General	RC271.C5 O4 2005	V. 1 Ej. 01	Disponible		089063

Incluye referencias bibliográficas.

1. Targeting of the EGFR as a modulator of cancer chemotherapy.--
2. Cyclin-dependent kinase inhibitors in combination chemotherapy.--
3. Development of protein kinase C and cyclin-dependent kinase inhibitors as potentiators of cytotoxic drug action in leukemia.--
4. Carboxyamidotriazole, an inhibitor of nonvoltage-operated calcium entry: single-agent and combination therapy for ovarian carcinoma.--
5. Targeted F-particle therapy: a rational approach to drug development in hematologic diseases and solid tumors.--
6. Pharmacological modulation of fluoropyrimidines: building on the lessons of the past.--
7. Development of inhibitors of HER2 with taxanes: new directions in breast cancer therapy.--
8 Targeting NF-PB to increase the activity of cisplatin in solid tumors.--
9. Combinations of chemotherapy and G3139, an antisense Bcl-2 oligonucleotide.--
10. Use of animal models to evaluate signal transduction inhibitors as modulators of cytotoxic therapy.

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

Área de Ciencias de la Salud